Daily Health
·18/03/2026
If you had chickenpox as a kid, the virus that caused it is still with you. For roughly one in three adults, it can reawaken decades later as shingles, a notoriously painful rash. This leaves many people wondering: is it better to get a vaccine to prevent it, or just wait and treat it if it happens? Let's compare the two paths.
This approach focuses on preventing the virus from reactivating in the first place.
Mechanism of Action: The modern shingles vaccine, Shingrix, is a two-dose series that powerfully boosts your immune system's ability to keep the varicella-zoster virus dormant and under control.
Benefits: Clinical studies show Shingrix is over 90% effective at preventing shingles in adults 50 and older. It also dramatically reduces the risk of the most common complication, postherpetic neuralgia—a severe nerve pain that can last for months or even years after the rash is gone. Furthermore, a growing body of research provides strong evidence that shingles vaccination is associated with a significantly lower risk of developing dementia. Some early studies also suggest a potential link to a reduced risk of stroke and heart attack.
Limitations: The primary drawbacks are temporary side effects. Many people experience a sore arm, and some report mild, flu-like symptoms such as fatigue or body aches that typically resolve within a couple of days.
Ideal Use Case: The CDC recommends the vaccine for all adults 50 and older, as well as for adults 19 and older with weakened immune systems.
This strategy involves managing shingles only after the illness has already begun.
Mechanism of Action: The primary treatment is a course of antiviral medications. These drugs work by stopping the virus from multiplying further, helping your body fight off the active infection.
Benefits: When started promptly, antiviral medication can help shorten the duration of the shingles rash and make the episode less severe.
Limitations: Timing is critical. Antivirals are most effective when started within 72 hours of the rash first appearing, a window that can be easy to miss. This approach is entirely reactive; it does nothing to prevent the initial pain and discomfort of the illness. Crucially, it does not reliably prevent the development of long-term complications like postherpetic neuralgia and offers none of the potential protective benefits against dementia.
Ideal Use Case: This is the necessary course of action for anyone who has already developed an active case of shingles.
When placed side-by-side, the choice becomes clearer. Treating an active infection is a fallback plan with a tight deadline and no guarantees against long-term pain. In contrast, vaccination offers a highly effective, proactive way to prevent the illness and its most severe consequences. The potential long-term cognitive benefits add significant weight to the preventative approach. For those eligible, the evidence supports vaccination not just as a defense against a painful rash, but as an investment in long-term health and well-being.









